Ora Pharm turned cannabis red tape into a business: processing and export for others

Medicinal cannabis cultivator and manufacturer in Waikato, New Zealand, now selling processing and export services to other growers.

Cultivators will pay one licensed processor to handle certification and export, making Ora the gateway for NZ product to CanXChange's Australian exchange.

Founder and chief executive Zoe Reece built Ora Pharm as a medicinal cannabis grower in Waikato, then in June 2024 opened its licensed processing and export capability to cultivators across New Zealand, taking on the multi-layered certification process that was the industry's main barrier to growth.

CanXChange — an AI-powered B2B cannabis trading platform that expanded from Europe into Australia — selected Ora as its only New Zealand supplier, meaning any NZ product reaching the Aussie exchange had to be funnelled through the firm. The backdrop was brutal: Pharmac declined to fund medicinal cannabis for anxiety, pain or insomnia, listed peers Cannasouth (administrators in March 2024) and Rua Bioscience were struggling, and post-election red-tape reforms stalled in Cabinet.

Compliance was the industry's declared growth barrier, so selling compliance-as-a-service attacks the widest pain.

The CanXChange exclusivity converts a service line into a chokepoint: NZ product reaches Australia only through Ora.

B2B revenue diversifies away from a domestic market Pharmac refuses to subsidise.

The pitch rides the wine-industry analogy regulators themselves used — agriculture exports as the sector's future.

When an industry's bottleneck is compliance, sell the compliance: the licensed player becomes the tollbooth everyone must pass through.

As of June 2024 Ora was raising $7.5M for commercial greenhouses it said could lift revenue to $20M, while industry-wide red-tape concessions awaited Cabinet approval under the new government.